IGF-1 treatment of multiple myeloma cells led to reduced histone H3 tail Lys9 (H3K9) acetylation, and increased H3K9 dimethylation, which contributed to the silencing of the bim and foxO3 genes [247]. The gene discussed is FOXO3; the disease is plasma cell myeloma.